10 individually packed test cassettes for detection of influenza virus type A and B antigens (nucleoproteins) extracted from nasal/nasopharyngeal swabs and nasal washes/aspirates of symptomatic patients
Package contents:
10 test cassettes
10 extraction tubes incl. dropper-caps
10 sterile swab
1 buffer (7.0 mL)
1 reagent holder
1 package insert
Exclusively for professional users
Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The NADAL® Influenza A/B Scan Test is a rapid chromatographic immunoassay for the qualitative detection of influenza virus type A and B antigens (nucleoproteins) extracted from nasal/nasopharyngeal swabs and nasal washes/aspirates of symptomatic patients. The test is intended as an aid in the rapid, differential diagnosis of influenza virus A and B infections. It is not intended for the detection of influenza C viral antigens. The qualitative measurement and evaluation of the test result is to be carried out using the nal von minden Colibri Point of Care reader. Negative results do not exclude influenza virus A or B infection and should be confirmed by cell culture or a molecular biological assay. The test is designed for professional use only.
Influenza is a highly contagious viral infection of the upper respiratory tract which is characterised by antigen variability, seasonality and the impact on the general population. Of the two main types (A and B) of influenza viruses, Influenza A subtypes are differentiated by antigen variability of the surface glycoproteins (hemagglutinin and neuraminidase). Influenza A virus is the most prevalent and is associated with the most serious epidemics. Influenza can cause severe complications such as bronchitis or pneumonia, particularly in children, elderly people or people with chronic respiratory disease. Yet, it most commonly occurs as a mild viral infection transmitted by respiratory secretions through sneezing or coughing. There are many other viral infections that can mimic influenza symptoms, making laboratory tests necessary to distinguish it from other acute respiratory infections. New effective antivirals are available since the late 1990s but these drugs are effective if administered early (before 48 hours after the onset of the illness). Virus isolation is still considered as the gold standard method for influenza diagnosis, with a sensitivity of nearly 100% after 3 days. However, patient health care and economic costs could be greatly improved by the use of rapid, specific and sensitive tests for antigen detection in order to enable a successful antiviral treatment.
The device is not included in the scope of delivery.
